Rising Ubiquity of Lifestyle Diseases to Drive IVIG Market

The global intravenous immunoglobulin (IVIG) market is prognosticated to witness solid growth in the coming years.  The market’s vendor landscape features high amount of consolidation. The leading four players, Grifols S.A., CSL Behring LLC, Baxalta Incorporated, and Octapharma AG, held over two-thirds of the overall market share in 2017, with Grifols S.A. holding maximum traction in the market. The dominance of this company could be attributed to the strong geographical presence acquired by the company. With a low number of vendors in the market, the market has an oligopolistic nature. This has fostered vigorous competition among the market participants. In order to ensure that the vendors leave their footprint in the industry, enterprises are adopting several strategies to gain market traction, such as mergers and acquisitions, and regional expansion. For instance, CSL Behring LLC recognized the large unmet demand for blood plasma and bio-therapeutics in Russia, and started operations in the country recently.

The global market for intravenous immunoglobulin (IVIG) market is predicted to rise at an 8.5 percent CAGR from 2017 to 2024. The market, which stood at USD 8419.7 million in 2017, is expected to reach an estimated value of USD 14,923 million in 2024. The end-user segment of hospitals currently dominates the global IVIG market, accounting for over 60 percent of the overall market share. Geographically, North America is the leading regional market, holding over 45 percent of the market.  Sedentary lifestyle habits along with incrementing consumption of saturated fats, salt, sugars, less physical activities, and high alcohol consumption are contributing to the high prevalence of chronic lifestyle diseases. The growing ubiquity of lifestyle associated disorders such as obesity and antibody deficiency disorders are key factors anticipated to fuel the growth of the IVIG market in the forthcoming years.

The global intravenous immunoglobulin market is also witnessing a solid growth from the increasing number of patients with bleeding disorders, the surge in number of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) patients, and the expanding pool of geriatric population. Moreover, increasing spending habits of users in the healthcare sector is also positively impacting the growth of intravenous immunoglobulin market. Additionally, there has been increased adoption of technological innovations such as purification methods, advanced production technologies, and usage of off level indications. The swift uptake of such innovations is supporting the rapid growth of market. This is also responsible for providing rich opportunities to companies operating in the global intravenous immunoglobulin market.

Several administrative associations have imposed stringent guidelines for appropriate usage of intravenous immunoglobulin products. Moreover, the treatment costs associated with IVIG are considerably high, which could hamper the growth of intravenous immunoglobulin market to some extent. A large percentage of patients cannot afford intravenous immunoglobulin products, due to high cost of their treatment. Intravenous immunoglobulin products are very expensive as the materials required to produce them cost more and the manufacturing process requires a significant amount of blood samples from donors.

On the other hand, according to the W.H.O, there are over 50 different Primary Immune Deficiency (PID’s) such as specific antibody deficiency, X-lined hypo-gamma-globulinemia, and others at the present time, and these patients are in dire need of IVIG therapy. Further, the increase in approval of intravenous immunoglobulin (IVIG) drugs from the Food and Drug Administration (FDA), European Medicine Agency (EMA), and government is expected to accelerate the sales of immunoglobulin in the forthcoming years, fuelling market growth. – Transparency Market Research